BioXcel Therapeutics (BTAI) Common Equity (2017 - 2026)

BioXcel Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.

• On a quarterly basis, Common Equity fell 17.05% year-over-year to -$105.5 million in Q1 2026; TTM through Mar 2026 was -$105.5 million, a 17.05% decrease from a year earlier, with the FY2025 full-year figure at -$95.5 million, down 2.54% from the prior year.
• Common Equity declined to -$105.5 million in Q1 2026 per BTAI's latest filing, from -$95.5 million in the prior quarter.
• Across five years, Common Equity topped out at $194.0 million in Q1 2022 and bottomed at -$107.7 million in Q2 2025.
• The 5-year median for Common Equity is -$72.4 million (2024), against an average of -$17.0 million.
• Across the five-year window, Common Equity increased 3.9% in 2022 and slumped 1367.07% in 2024, its largest moves.
• Year by year, Common Equity stood at $76.8 million in 2022, then tumbled by 173.6% to -$56.5 million in 2023, then sank by 64.76% to -$93.1 million in 2024, then fell by 2.54% to -$95.5 million in 2025, then decreased by 10.56% to -$105.5 million in 2026.
• Per Business Quant, the three latest BTAI Common Equity figures stand at -$105.5 million (Q1 2026), -$95.5 million (Q4 2025), and -$88.9 million (Q3 2025).